Clinical Trials Logo

Filter by:
NCT ID: NCT04344535 Terminated - COVID Clinical Trials

Convalescent Plasma vs. Standard Plasma for COVID-19

Start date: April 8, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find out if transfusion of blood plasma containing antibodies against COVID-19 (anti-SARS-CoV-2), which were donated from a patient who recovered from COVID-19 infection, is safe and can treat COVID-19 in hospitalized patients. Antibodies are blood proteins produced by the body in response to a virus and can remain in the person's bloodstream (plasma) for a long time after they recover. Transferring plasma from a person who recovered from COVID-19 may help neutralize the virus in sick patients' blood, and/or reduce the chances of the infection getting worse.

NCT ID: NCT04344444 Terminated - COVID-19 Clinical Trials

Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease

RCT
Start date: April 13, 2020
Phase: Phase 3
Study type: Interventional

This study proposes to evaluate clinical outcomes and viral load in COVID-19 infected patients with early moderate and severe disease admitted to the hospital and randomized to one of three arms. Patients will be randomized to supportive care, OR hydroxychloroquine alone, OR hydroxychloroquine and azithromycin.

NCT ID: NCT04343976 Terminated - COVID-19 Clinical Trials

Pegylated Interferon Lambda Treatment for COVID-19

Start date: June 22, 2020
Phase: Phase 2
Study type: Interventional

Prospective randomized trial to assess the antiviral efficacy of Pegylated Interferon Lambda (180 mcg SC injection) vs.placebo in up to 20 subjects with COVID-19 infection.

NCT ID: NCT04343755 Terminated - COVID-19 Clinical Trials

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

Start date: April 9, 2020
Phase: Phase 2
Study type: Interventional

- This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection. - Subjects will be considered as having completed the study after 60 (+/- 3) days, unless consent withdrawal or death occurs first. - Interim analysis will be permitted as described in the statistical section 8. - The final analysis will be conducted once the last subject completes the day 60 visit or withdraws from the study.

NCT ID: NCT04343248 Terminated - COVID-19 Clinical Trials

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

Start date: May 12, 2020
Phase: Phase 3
Study type: Interventional

Trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF residents.

NCT ID: NCT04343235 Terminated - Clinical trials for Hypertension, Pregnancy-Induced

Postpartum Management of Gestational Hypertensive Disorders Using Furosemide

Start date: May 1, 2020
Phase: Phase 4
Study type: Interventional

- The main purpose of this study is to learn if incorporating a loop diuretic such as furosemide along with labetalol in the routine management of postpartum gestational hypertensive disorders could lower the need for additional anti-hypertensive agents to control blood pressures, improve blood pressures (as measured by systolic blood pressure, diastolic blood pressure and mean arterial blood pressures), shorten hospital stays and decrease readmissions for patients with gestational hypertensive disorders. - Based on a study by Veena et al1, there is reason to believe that the addition of furosemide to other anti-hypertensives may help decrease the need to add or increase the dose of medication to control blood pressures. There may be potential to shorten hospital stays and decrease readmissions, as well. Collecting data will be done using a prospective, randomized 1:1 controlled study assigning postpartum patients with a gestational hypertensive diagnosis to either labetalol alone or labetalol plus furosemide. - The study will be performed in the postpartum wing of Miami Valley Hospital Main Campus and would use patients who have consented to participate in the study with enrollees coming from the OB Staff population.

NCT ID: NCT04342897 Terminated - COVID-19 Clinical Trials

A Study of LY3127804 in Participants With COVID-19

Start date: April 20, 2020
Phase: Phase 2
Study type: Interventional

A randomized, double-blind, placebo-controlled, clinical trial of LY3127804 in participants who are hospitalized with pneumonia and presumed or confirmed COVID-19.

NCT ID: NCT04342689 Terminated - COVID-19 Clinical Trials

The Role of Resistant Starch in COVID-19 Infection

Start date: June 3, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This study is a multicenter randomized trial to evaluate the efficacy of administering a dietary supplement containing resistant starch to non-hospitalized COVID-19 positive subjects, The intervention will begin as soon as possible after subjects test positive for COVID-19 and continue for 14 days. Investigators hypothesize that short-term administration of a dietary supplement containing resistant starch has the potential to reduce rates of hospitalization and improve time to clinical recovery and symptoms in non-hospitalized COVID-19 positive patients.

NCT ID: NCT04342117 Terminated - Lymphoma Clinical Trials

Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL

REAL
Start date: April 23, 2020
Phase:
Study type: Observational [Patient Registry]

This study will assess whether there are differences in effectiveness and safety outcomes among PI3K-treated patients in a real world registry, compared to patients treated in clinical trials.

NCT ID: NCT04341740 Terminated - Clinical trials for Renal Cell Carcinoma

Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma

WindMIL-001
Start date: July 22, 2020
Phase: N/A
Study type: Interventional

The purpose of this research is to collect health-related information as well as bone marrow and blood specimens to determine if a new form of treatment for patients with kidney and bladder cancer may be possible.